KLK3 and prostate cancer: In this regard, to treat metastatic castration-resistant prostate cancer, a CURATE.AI was utilized to guide the dosing of ZEN-3694 (a bromodomain inhibitor) and enzalutamide that were used in combination to treat metastatic castration-resistant prostate cancer to lessen serum prostate-specific antigen (PSA) levels.